Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Integrative genomics of checkpoint blockade response in advanced non-small cell lung cancer
    Meeting Abstract

    Ravi, A.; Gainor, J.; Arniella, M.; Stewart, C.; Freeman, S.; Awad, M. M.; Forde, P.; Anagnostou, V.; Henick, B.; Riess, J. W.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Exploring the impact of infertility and its treatments on risk of ovarian cancer
    Meeting Abstract

    Lee, A. W.; Phung, M. T.; Jensen, A.; Wu, A. H.; Cramer, D. W.; Modugno, F.; Harris, H.; Doherty, J. A.; Schildkraut, J.; Terry, K. L.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas
    Meeting Abstract

    Gounder, M. M.; Schwartz, G. K.; Jones, R. L.; Chawla, S. P.; Chua-Alcala, V. S.; Stacchiotti, S.; Wagner, A. J.; Cote, G. M.; Maki, R. G.; Kosela-Paterczyk, H.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Ceralasertib and olaparib in the treatment of homologous recombination repair (HRR)-deficient platinum-sensitive ovarian cancer after progression on PARP inhibitors
    Meeting Abstract

    Shapiro, G. I.; Basu, B.; El-Khoueiry, A.; Postel-Vinay, S.; Im, S. A.; Rha, S. Y.; Friedman, C. F.; Italiano, A.; Kim, Y. M.; Lim, M. C.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year analysis of CodeBreaK100
    Meeting Abstract

    Dy, G. K.; Govindan, R.; Velcheti, V.; Falchook, G. S.; Italiano, A.; Wolf, J.; Sacher, A. G.; Takahashi, T.; Ramalingam, S. S.; Dooms, C.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Higher levels of circulating exhausted T-cells at pre- and post-infusion negatively associated with clinical efficacy in tisagenlecleucel (Tisa-cel) treated relapsed/refractory large B-cell lymphoma (r/r LBCL) patients (pts) in JULIET trial
    Meeting Abstract

    Jäger, U.; Han, X.; Germano, D.; Quinn, D.; Gaddis, D.; Masood, A.; Mulvey, T.; Mataraza, J.; Bishop, M. R.; Salles, G.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • A first-in-human phase 1 study of NL-201 in patients with relapsed or refractory cancer
    Meeting Abstract

    Naing, A.; Callahan, M.; Costello, B. A.; Curti, B.; Hall, E.; Hansen, A.; Long, G. V.; Joshua, A. M.; Wetmore, C.; Weickhardt, A.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • A phase 1a/1b study of STK-012, an α/β IL-2 receptor selective partial agonist as monotherapy and in combination with pembrolizumab in advanced solid tumors (NCT05098132)
    Meeting Abstract

    Spigel, D.; Spira, A.; Zamarin, D.; McDermott, D. F.; Luke, J.; Heymach, J. V.; Previs, R.; Sullivan, R.; Gandhi, L.; Azrilevich, A.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Amcenestrant, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/HER2-advanced breast cancer (aBC): Combined biomarker analyses from a phase 1/2 study in postmenopausal women and a phase 1 study in postmenopausal Japanese women
    Meeting Abstract

    Iwata, H.; Bardia, A.; Lord, S.; Linden, H. M.; Campone, M.; Tamura, K.; Yonemori, K.; Mukohara, T.; Combeau, C.; Ternes, N.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • A phase I, open-label, dose-escalation study investigating a low-density lipoprotein receptor-related protein (LRP) 5/6 inhibitor, BI 905677, in patients with advanced solid tumors
    Meeting Abstract

    Élez, E.; Lenz, H. J.; de Jonge, M.; Yaeger, R.; Doi, T.; Pronk, L.; Teufel, M.; Marzin, K.; Tabernero, J.
    Cancer Research (2022)

    Fulltext@MSK | Save